Phase II study of vismodegib in patients with SMO or PTCH1 mutated tumors: Results from NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol T.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Anne S. Tsao, Zihe Song, Alan Loh Ho, Janice M. Mehnert, Edith P. Mitchell, John Joseph Wright, Naoko Takebe, Robert James Gray, Victoria Wang, Lisa McShane, Larry V. Rubinstein, David R. Patton, P. Mickey Williams, Stanley R. Hamilton, Barbara A. Conley, Carlos L. Arteaga, Lyndsay Harris, Peter J. O'Dwyer, Alice P. Chen, Keith Flaherty
Institutions: The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, Thomas Jefferson University, Sidney Kimmel Cancer Center, National Institutes of Health, National Cancer Institute, Dana-Farber Cancer Institute, City Of Hope National Medical Center, City of Hope, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Pennsylvania Hospital, University of Pennsylvania, Harvard University, Massachusetts General Hospital
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4286294894